REFERENCES
1. Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.
2. Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:1388-9.
3. Shang Y, Nasr P, Widman L, Hagström H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022;76:1495-505.
4. Foley CN, Staley JR, Breen PG, et al. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat Commun. 2021;12:764.
5. Li P, Ji H, Cheng S. Heart-liver axis implications of the new steatotic liver disease nomenclature. Lancet Gastroenterol Hepatol. 2023;8:1071-2.
6. Baskin KK, Bookout AL, Olson EN. The heart-liver metabolic axis: defective communication exacerbates disease. EMBO Mol Med. 2014;6:436-8.
7. Zhou J, Bai L, Zhang XJ, Li H, Cai J. Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications. Hepatology. 2021;74:2839-47.
8. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903-13.
9. Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867-75.
10. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694-701.
11. Oh JH, Jun DW. Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): insights into regional and ethnic differences. Clin Mol Hepatol. 2024;30:168-70.
12. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
13. Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD. Curr Obes Rep. 2024;13:510-31.
14. Isaak A, Praktiknjo M, Jansen C, et al. Myocardial fibrosis and inflammation in liver cirrhosis: MRI study of the liver-heart axis. Radiology. 2020;297:51-61.
15. Burelle C, Clapatiuc V, Deschênes S, et al. A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis. Commun Biol. 2024;7:356.
16. Anstee QM, Darlay R, Cockell S, et al; EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆. J Hepatol. 2020;73:505-15.
17. Claussnitzer M, Cho JH, Collins R, et al. A brief history of human disease genetics. Nature. 2020;577:179-89.
18. Sonehara K, Okada Y. Leveraging genome-wide association studies to better understand the etiology of cancers. Cancer Sci. 2025;116:288-96.
19. Lau PP, Wei CY, Lin MR, Chou WH, Wan YY, Chang WC. Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities. Cell Biosci. 2025;15:19.
20. Torgersen K, Rahman Z, Bahrami S, et al. Shared genetic loci between depression and cardiometabolic traits. PLoS Genet. 2022;18:e1010161.
21. Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72:1196-209.
22. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40-52.
23. Hong X, Wu Z, Cao W, et al. Cardiometabolic traits in adult twins: heritability and BMI impact with age. Nutrients. 2022;15:164.
24. Ghodsian N, Abner E, Emdin CA, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med. 2021;2:100437.
25. Bulik-Sullivan B, Finucane HK, Anttila V, et al; ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236-41.
26. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658-65.
27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377-89.
28. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304-14.
29. Hu X, Zhao J, Lin Z, et al. Mendelian randomization for causal inference accounting for pleiotropy and sample structure using genome-wide summary statistics. Proc Natl Acad Sci U S A. 2022;119:e2106858119.
30. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-75.
31. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
32. O’Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. Nat Genet. 2018;50:1728-34.
33. Turley P, Walters RK, Maghzian O, et al; 23andMe Research Team, Social Science Genetic Association Consortium. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet. 2018;50:229-37.
34. Zhu X, Feng T, Tayo BO, et al; COGENT BP Consortium. Meta-analysis of correlated traits via summary statistics from GWASs with an application in hypertension. Am J Hum Genet. 2015;96:21-36.
35. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
36. Wallace C. Statistical testing of shared genetic control for potentially related traits. Genet Epidemiol. 2013;37:802-13.
37. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48:245-52.
38. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481-7.
39. Bakshi A, Zhu Z, Vinkhuyzen AA, et al. Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. Sci Rep. 2016;6:32894.
40. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.
41. Consortium. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318-30.
42. Feng H, Mancuso N, Gusev A, et al. Leveraging expression from multiple tissues using sparse canonical correlation analysis and aggregate tests improves the power of transcriptome-wide association studies. PLoS Genet. 2021;17:e1008973.
43. Xu S, Hu E, Cai Y, et al. Using clusterProfiler to characterize multiomics data. Nat Protoc. 2024;19:3292-320.
44. Dougherty JD, Schmidt EF, Nakajima M, Heintz N. Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res. 2010;38:4218-30.
45. Dai Y, Hu R, Liu A, et al. WebCSEA: web-based cell-type-specific enrichment analysis of genes. Nucleic Acids Res. 2022;50:W782-90.
46. Xiong X, Kuang H, Ansari S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019;75:644-60.e5.
47. Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888-902.e21.
48. Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16:1289-96.
49. Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163-72.
50. Saul D, Kosinsky RL, Atkinson EJ, et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat Commun. 2022;13:4827.
51. Cotto KC, Wagner AH, Feng YY, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46:D1068-73.
52. Ursu O, Holmes J, Bologa CG, et al. DrugCentral 2018: an update. Nucleic Acids Res. 2019;47:D963-70.
53. Barbarino JM, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB: a worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018;10:e1417.
54. Mathews SE, Kumar RB, Shukla AP. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Curr Opin Endocrinol Diabetes Obes. 2018;25:315-20.
55. Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. J Clin Med. 2021;10:467.
56. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793-801.
57. Xie W, Gan J, Zhou X, et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti. Cell Metab. 2024;36:1269-86.e9.
58. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75:275-84.
59. Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: a Mendelian randomization study. Hepatology. 2023;77:230-8.
60. Park J, Kim G, Kim H, Lee J, Jin SM, Kim JH. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. Cardiovasc Diabetol. 2022;21:287.
61. Liu Y, Wang J, Jin R, et al. Associations of metabolic dysfunction-associated fatty liver disease with peripheral artery disease: prospective analysis in the UK biobank and ARIC study. J Am Heart Assoc. 2024;13:e035265.
62. Pandey N, Anand SK, Kaur H, et al. Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis. J Thromb Haemost. 2024;22:3572-80.
63. Cho EJ, Chung GE, Yoo JJ, et al. Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups. Cardiovasc Diabetol. 2024;23:340.
64. Jia Y, Li Y, Yu J, et al. Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm. Nutr Metab Cardiovasc Dis. 2024;34:953-62.
65. Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106:e4360-71.
66. Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology. 2018;68:1308-18.
67. Hu Y, Tang W, Liu Y, et al. Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease. Hypertens Res. 2024;47:1811-21.
68. Yuan M, He J, Hu X, et al. Hypertension and NAFLD risk: insights from the NHANES 2017-2018 and Mendelian randomization analyses. Chin Med J. 2024;137:457-64.
69. Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories. Hypertension. 2020;76:562-8.
70. Song Q, Ling Q, Fan L, et al. Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension. Chin Med J. 2023;136:1591-7.
71. Iwamoto S, Boonvisut S, Makishima S, Ishizuka Y, Watanabe K, Nakayama K. The role of TRIB1 in lipid metabolism; from genetics to pathways. Biochem Soc Trans. 2015;43:1063-8.
72. Functional analysis of the TRIB1 associated locus linked to plasma triglycerides and coronary artery disease. J Am Heart Assoc. 2016;5:e002056.
73. Kitamoto A, Kitamoto T, Nakamura T, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J. 2014;61:683-9.
74. Liu Q, Xue F, Meng J, et al. TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population. Lipids Health Dis. 2019;18:61.
75. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:E271-88.
76. Goldberg IJ. 2017 George Lyman Duff memorial lecture: fat in the blood, fat in the artery, fat in the heart: triglyceride in physiology and disease. Arterioscler Thromb Vasc Biol. 2018;38:700-6.
77. Chalasani N, Vilar-Gomez E, Loomba R, et al. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024;80:1212-26.
78. Bruschi FV, Tardelli M, Herac M, Claudel T, Trauner M. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver Int. 2020;40:1098-110.
79. Zhang G, Jiang W, He F, et al. LDL-C and TC mediate the risk of PNPLA3 inhibition in cardiovascular diseases. J Clin Endocrinol Metab. 2025;110:e231-8.
80. Chen G, Shriner D, Zhang J, et al. Additive genetic effect of GCKR, G6PC2, and SLC30A8 variants on fasting glucose levels and risk of type 2 diabetes. PLoS One. 2022;17:e0269378.
81. Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al; DESIR Study Group. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes. 2008;57:2253-7.
82. Socha P, Wierzbicka A, Neuhoff-Murawska J, Wlodarek D, Podlesny J, Socha J. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Rocz Panstw Zakl Hig. 2007;58:129-37.
83. Petit JM, Masson D, Guiu B, et al. GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetol. 2016;53:237-42.
84. Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2020;63:253-60.
85. Ll, Siersbæk M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 2012;23:631-9.
86. Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786.
87. El Cheikh J, Hamed F, Rifi H, Dakroub AH, Eid AH. Genetic polymorphisms influencing antihypertensive drug responses. Br J Pharmacol. 2025;182:929-50.
88. Du Y, Wu L, Wang L, Reiter RJ, Lip GYH, Ren J. Extracellular vesicles in cardiovascular diseases: from pathophysiology to diagnosis and therapy. Cytokine Growth Factor Rev. 2023;74:40-55.
89. Li W, Li Y, Chu Y, et al. PLCE1 promotes myocardial ischemia-reperfusion injury in H/R H9c2 cells and I/R rats by promoting inflammation. Biosci Rep. 2019;39:BSR20181613.
90. Evangelou E, Warren HR, Mosen-Ansorena D, et al; Million Veteran Program. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412-25.
91. DeForest N, Wang Y, Zhu Z, et al. Genome-wide discovery and integrative genomic characterization of insulin resistance loci using serum triglycerides to HDL-cholesterol ratio as a proxy. Nat Commun. 2024;15:8068.
92. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092.
93. Castillo-Leon E, Connelly MA, Konomi JV, Caltharp S, Cleeton R, Vos MB. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis. Pediatr Obes. 2020;15:e12648.
94. Nass KJ, van den Berg EH, Faber KN, Schreuder TCMA, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study. Metabolism. 2017;72:37-46.
95. Chandrasekharan K, Alazawi W. Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy? Front Pharmacol. 2020;10:1413.
96. Widjaja AA, Singh BK, Adami E, et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology. 2019;157:777-92.e14.
97. Vos DY, van de Sluis B. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Mol Metab. 2021;50:101146.
98. Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Invest. 2019;129:546-55.
99. Jaitin DA, Adlung L, Thaiss CA, et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell. 2019;178:686-98.e14.
100. Cochain C, Vafadarnejad E, Arampatzi P, et al. Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 2018;122:1661-74.
101. Magida JA, Leinwand LA. Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy. EMBO Mol Med. 2014;6:482-95.
102. Jamialahmadi O, Mancina RM, Ciociola E, et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology. 2021;160:1634-46.e7.
103. van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF. Plasma ApoE elevations are associated with NAFLD: the PREVEND study. PLoS One. 2019;14:e0220659.
104. Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24:28-43.
105. Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep. 2021;21:15.
106. Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. 2021;11:155.
107. Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111:737-47.
108. Brocker CN, Patel DP, Velenosi TJ, et al. Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. J Lipid Res. 2018;59:2140-52.
109. Sanderson LM, Boekschoten MV, Desvergne B, Müller M, Kersten S. Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver. Physiol Genomics. 2010;41:42-52.
110. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, et al. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 2008;7:496-507.
111. Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612.
112. Fang J, Li L, Cao X, et al. Transmissible endoplasmic reticulum stress mediated by extracellular vesicles from adipocyte promoting the senescence of adipose-derived mesenchymal stem cells in hypertrophic obesity. Oxid Med Cell Longev. 2022;2022:7175027.
113. Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85α and p85β, interact with XBP-1 and increase its nuclear translocation. Nat Med. 2010;16:429-37.
114. Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568-76.
115. Fernandes-da-Silva A, Miranda CS, Santana-Oliveira DA, et al. Endoplasmic reticulum stress as the basis of obesity and metabolic diseases: focus on adipose tissue, liver, and pancreas. Eur J Nutr. 2021;60:2949-60.
116. Auer H, Cabalo DG, Rodríguez-Cruces R, et al. From histology to macroscale function in the human amygdala. Elife. 2025;13:RP101950.
117. Gu Y, Zhang W, Hu Y, Chen Y, Shi J. Association between nonalcoholic fatty liver disease and depression: a systematic review and meta-analysis of observational studies. J Affect Disord. 2022;301:8-13.
118. Shea S, Lionis C, Kite C, et al. Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis. Front Endocrinol. 2024;15:1357664.
119. Qiao Y, Ding Y, Li G, Lu Y, Li S, Ke C. Role of depression in the development of cardiometabolic multimorbidity: findings from the UK Biobank study. J Affect Disord. 2022;319:260-6.
120. Yang W, Li W, Wang S, et al. Association of cardiometabolic multimorbidity with risk of late-life depression: a nationwide twin study. Eur Psychiatry. 2024;67:e58.
121. Celikbilek A, Celikbilek M, Bozkurt G. Cognitive assessment of patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2018;30:944-50.
122. Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79:1319-26.
123. McCracken C, Raisi-Estabragh Z, Veldsman M, et al. Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants. Nat Commun. 2022;13:7839.
124. Binesh A, Devaraj SN, Halagowder D. Atherogenic diet induced lipid accumulation induced NFκB level in heart, liver and brain of Wistar rat and diosgenin as an anti-inflammatory agent. Life Sci. 2018;196:28-37.
125. Zheng J, Xu M, Yang Q, et al. Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study. EBioMedicine. 2023;96:104803.
126. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54:1631-9.
127. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305-15.
128. Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40:1364-72.
129. Cosentino F, Verma S, Ambery P, et al. Cardiometabolic risk management: insights from a European society of cardiology cardiovascular round table. Eur Heart J. 2023;44:4141-56.
130. Wu S, Li Y, Zhang Y, et al. Sex and age differences in the association between metabolic dysfunction-associated fatty liver disease and heart failure: a prospective cohort study. Circ Heart Fail. 2024;17:e010841.
